Clinical Commissioning Policy: Tolvaptan for hyponatraemia secondary to the Syndrome of Inappropriate Antidiuretic Hormone (SIADH) in patients requiring cancer chemotherapy

Document first published:
Page updated:
Topic:
,
Publication type:
This document describes the evidence that has been considered by NHS England informulating a policy to routinely commission tolvaptan for hyponatraemia secondary to SIADH in patients requiring cancer chemotherapy.

Document

Clinical Commissioning Policy: Tolvaptan for hyponatraemia secondary to the Syndrome of Inappropriate Antidiuretic Hormone (SIADH) in patients requiring cancer chemotherapy

Clinical Commissioning Policy: Tolvaptan for hyponatraemia secondary to the Syndrome of Inappropriate Antidiuretic Hormone (SIADH) in patients requiring cancer chemotherapy

  • PDF
  • 350 KB
  • 22 pages